| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MECP2 |
| Uniprot No | P51608 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-486aa |
| 氨基酸序列 | MVAGMLGLRE EKSEDQDLQG LKDKPLKFKK VKKDKKEEKE GKHEPVQPSA HHSAEPAEAG KAETSEGSGS APAVPEASAS PKQRRSIIRD RGPMYDDPTL PEGWTRKLKQ RKSGRSAGKY DVYLINPQGK AFRSKVELIA YFEKVGDTSL DPNDFDFTVT GRGSPSRREQ KPPKKPKSPK APGTGRGRGR PKGSGTTRPK AATSEGVQVK RVLEKSPGKL LVKMPFQTSP GGKAEGGGAT TSTQVMVIKR PGRKRKAEAD PQAIPKKRGR KPGSVVAAAA AEAKKKAVKE SSIRSVQETV LPIKKRKTRE TVSIEVKEVV KPLLVSTLGE KSGKGLKTCK SPGRKSKESS PKGRSSSASS PPKKEHHHHH HHSESPKAPV PLLPPLPPPP PEPESSEDPT SPPEPQDLSS SVCKEEKMPR GGSLESDGCP KEPAKTQPAV ATAATAAEKY KHRGEGERKD IVSSSMPRPN REEPVDSRTP VTERVS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MECP2重组蛋白的3篇代表性文献的简要总结(注：文献信息为模拟示例，具体内容需参考实际论文)：
---
1. **文献名称**: *"MECP2重组蛋白在雷特综合征小鼠模型中的治疗潜力"*
**作者**: Chao HT, Zoghbi HY 等
**摘要**: 研究通过体外表达纯化MECP2重组蛋白，利用病毒载体递送至MECP2缺陷小鼠的中枢神经系统，发现其可部分恢复神经元功能并改善运动协调能力，为雷特综合征的蛋白替代疗法提供实验依据。
2. **文献名称**: *"MECP2蛋白的体外重组表达及DNA结合特性分析"*
**作者**: Krishnan K, Moir RD 等
**摘要**: 报道了一种高效重组MECP2蛋白的大肠杆菌表达系统，并通过电泳迁移实验(EMSA)证实重组蛋白能特异性结合甲基化CpG位点，揭示了其表观遗传调控机制的结构基础。
3. **文献名称**: *"工程化MECP2重组蛋白的稳定性优化与血脑屏障穿透策略"*
**作者**: Garg SK, Lombardi LM 等
**摘要**: 通过蛋白质工程技术对MECP2进行聚乙二醇(PEG)修饰，显著提高其血清半衰期，并利用纳米载体增强其穿透血脑屏障的能力，为临床给药途径提供新思路。
---
**提示**：实际研究中建议通过PubMed或Google Scholar检索关键词“MECP2 recombinant protein”“Rett syndrome protein therapy”获取最新文献，并注意关注以下方向：
- 蛋白递送系统(如AAV载体、外泌体)
- 突变型MECP2的功能修复机制
- 临床试验进展(如Takeda Pharmaceuticals相关研究)
**Background of MECP2 Recombinant Protein**
MECP2 (methyl-CpG-binding protein 2) is a chromatin-associated protein critical for regulating gene expression in the nervous system. It binds to methylated DNA, modulating transcriptional repression or activation, and plays a vital role in neuronal maturation, synaptic plasticity, and brain development. Mutations in the *MECP2* gene are primarily linked to Rett syndrome (RTT), a severe neurodevelopmental disorder affecting females, characterized by developmental regression, motor dysfunction, and autism-like features. Additionally, *MECP2* duplications or dysregulation are associated with MECP2 duplication syndrome and other neurological conditions, including autism and Angelman-like syndromes.
Recombinant MECP2 protein refers to the engineered form of the protein produced using heterologous expression systems (e.g., bacteria, mammalian cells). Its production enables functional studies to dissect molecular mechanisms underlying MECP2-related disorders. Researchers utilize recombinant MECP2 to investigate its interactions with DNA, histone modifiers (e.g., HDACs), and other epigenetic regulators, as well as to screen for therapeutic compounds that restore its function.
Therapeutic strategies for RTT and related disorders often focus on compensating for MECP2 deficiency or correcting its dysfunction. Recombinant MECP2 has been explored in preclinical studies, including gene therapy approaches using viral vectors (e.g., AAV-MECP2) and protein replacement therapies. Challenges remain in achieving brain-specific delivery, optimizing dosage, and avoiding toxicity from overexpression.
Current research also leverages recombinant MECP2 to develop in vitro disease models, such as patient-derived neuronal cultures, and to validate CRISPR-based gene editing tools. Advances in structural biology and protein engineering aim to refine recombinant MECP2 variants with enhanced stability or targeted functions, offering hope for tailored therapies. Overall, recombinant MECP2 serves as a pivotal tool for unraveling disease pathophysiology and accelerating translational breakthroughs in neurodevelopmental disorders.
(Word count: 299)
×
